The Motley Fool

All I Want For Christmas Is… Optos Plc

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

One stock I’m keeping my eye on this festive season is Optos (LSE: OPTS), the Dunfermline-based medical outfit that creates, sells and leases retinal imaging devices around the world.

Optos develops some of the world’s foremost optical diagnostic and treatment devices, and despite its humble beginnings, sells most of its wares in the high-end US market.

5 Stocks For Trying To Build Wealth After 50

Markets around the world are reeling from the coronavirus pandemic… and with so many great companies trading at what look to be ‘discount-bin’ prices, now could be the time for savvy investors to snap up some potential bargains.

But whether you’re a newbie investor or a seasoned pro, deciding which stocks to add to your shopping list can be a daunting prospect during such unprecedented times.

Fortunately, The Motley Fool UK analyst team have short-listed five companies that they believe STILL boast significant long-term growth prospects despite the global upheaval…

We’re sharing the names in a special FREE investing report that you can download today. And if you’re 50 or over, we believe these stocks could be a great fit for any well-diversified portfolio.

Click here to claim your free copy now!

It’s true what they say — the eye really is the window of the body. The retina is one of the best early warning systems for conditions like heart disease, and even cancerous cells can be spotted early in retinal tissue.

Optos’s retinal imagery devices can do what others cannot — it is the only system capable of mapping as much as 82% of the retina and its all-important periphery, which is so hard to capture.

And with the release of new device Daytona, which weighs just 25kg and is scaled to fit in smaller doctors’ and optometrist offices, this high level of insight can now affordably be brought to patients around the world.

Optos recently reported annual results showing a 13% jump in underlying revenues, and I believe the company could have further to grow. With the shares making an assault on their all-time high, I still think these shares could play a blinder in the years ahead.

Is this little-known company the next ‘Monster’ IPO?

Right now, this ‘screaming BUY’ stock is trading at a steep discount from its IPO price, but it looks like the sky is the limit in the years ahead.

Because this North American company is the clear leader in its field which is estimated to be worth US$261 BILLION by 2025.

The Motley Fool UK analyst team has just published a comprehensive report that shows you exactly why we believe it has so much upside potential.

But I warn you, you’ll need to act quickly, given how fast this ‘Monster IPO’ is already moving.

Click here to see how you can get a copy of this report for yourself today

Mark Rogers has no position in any shares mentioned. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.